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Antigen-specific release of b-chemokines by anti-HIV-1 cytotoxic
T lymphocytes
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Sarah L. Rowland-Jones and Rodney E. Phillips
A major advance in understanding human
immunodeficiency virus (HIV) biology was the discovery
that the b-chemokines MIP-1a (macrophage
inflammatory protein-1a), MIP-1b (macrophage
inflammatory protein-1b) and RANTES (regulated on
activation, normal T-cell expressed and secreted) inhibit
entry of HIV-1 into CD4+ cells by blocking the critical
interaction between the CCR5 coreceptor and the V3
domain of the viral envelope glycoprotein gp120 [1,2].
CD8+ lymphocytes are a major source of b-chemokines
[3], but the stimulus for chemokine release has not
been well defined. Here, we have shown that
engagement of CD8+ cytotoxic T lymphocytes (CTLs)
with HIV-1-encoded human leukocyte antigen (HLA)
class I-restricted peptide antigens caused rapid and
specific release of these b-chemokines. This release
paralleled cytolytic activity and could be attenuated by
naturally occurring amino acid variation within the HLA
class I-restricted peptide sequence. Epitope variants
that bound to appropriate HLA class I molecules but
failed to stimulate cytolytic activity in CTLs also failed
to stimulate chemokine release. We conclude that
signalling through the T-cell receptor (TCR) following
binding of antigen results in b-chemokine release from
CTLs in addition to cytolytic activity, and that both
responses can be abolished by epitope mutation. These
results suggest that antigenic variation within HIV-1
might not only allow the host cell to escape lysis, but
might also contribute to the propagation of infection by
failing to activate b-chemokine-mediated inhibition of
HIV-1 entry.
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Results and discussion
Release of the β-chemokines MIP-1α, MIP-1β and
RANTES from HIV-1-specific CTL lines and clones
(Table 1) was quantified by immunoassay and compared
with lytic activity and interferon-γ (IFN-γ) production. In
all assays, significant β-chemokine release required the
appropriate peptide antigen bound to HLA class I; repre-
sentative data are shown in Figure 1. This extends earlier
work which demonstrated antigen-specific release of other
cytokines by CTLs [4] and supports studies that corre-
lated suppression of virus replication, as determined by
bioassay, with lytic activity [5,6].
Despite increasing evidence that CTLs control HIV-1
infection in vivo, the significance of naturally occurring
mutations within HIV-1 epitopes that reduce or abolish
CTL recognition [7] remains uncertain. Recent work has
suggested that evasion of CTL recognition contributes to
both viral persistence following infection and progression to
AIDS [8–10]. We therefore assessed the effect of naturally
occurring amino acid variation within epitopes, represented
in the experiments by synthetic peptides, on β-chemokine
release by CTLs and compared this with the effect on
cytolysis. In the donor 868 HLA-A2-restricted CTL line
specific for the epitope SLYNTVATL (single-letter amino
acid code), peptide variants with impaired ability to sensi-
tize targets for lysis also failed to stimulate maximal β-
chemokine release from CTLs when compared with
wild-type peptide (Figure 2) [11]. Similar results were
obtained for the 3F, 3L and 3F/5A peptide variants [11]
with the HLA-A2-restricted SLYNTVATL-specific CTL
clone from donor 003; the 6I variant [10] with the HLA-
B27-restricted KRWIIMGLNK-specific CTL line from
Table 1
CTL lines and clones used in this work. 
Epitope HIV-1 protein HLA Donor Line/clone
(amino acids) restriction
SLYNTVATL p17 Gag 77–85 A2 868 Line
SLYNTVATL p17 Gag 77–85 A2 868 Clone
SLYNTVATL p17 Gag 77–85 A2 003 Clone
ISPRTLNAW p24 Gag 147–155 B57 422 Line
KRWIIMGLNK p24 Gag 263–272 B27 868 Line
VIYQYMDDL Pol 346–354 A2 868 Clone
ILKEPVHGV Pol 476–484 A2 SC6 Line
VRYPLTFGW Nef 137–145 A24 106 Line
All epitope amino acids are numbered with reference to HIV-1 LAI
amino acid numbering.
donor 868; the 3F/5A variant [11] with the HLA-A2-
restricted SLYNTVATL-specific CTL clone from donor
868; and the 3C variant [12,13] with the HLA-A2-restricted
VIYQYMDDL-specific CTL clone from donor 868 (data
not shown). The observation that β-chemokine production
parallels cytolytic activity with both wild-type and variant
epitopes over a range of peptide concentrations suggests
that naturally occurring epitope mutation facilitates HIV-1
evasion of both lytic and suppressor functions of CTLs. 
Individuals that are homozygous for a mutant allele of
CCR5 in which a 32 base-pair deletion causes a frameshift
resulting in a non-functional receptor have been shown to
be resistant to HIV-1 infection despite repeated exposure
[2]; in addition, there is some evidence that HIV-1 seropos-
itive heterozygotes progress more slowly to AIDS [2]. As
cellular CCR5 expression levels correlate with infectability
by macrophage-tropic HIV-1 [14], receptor blockade by
endogenous β-chemokines might inhibit the propagation of
infection within infected individuals, thereby slowing
disease progression. The capacity of β-chemokines to
control HIV-1 infection in vivo remains unknown, however;
inhibition of virus entry does not necessarily correlate with
suppression of viral replication [15]. Furthermore, CCR5
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(a) Donor SC6 ILKEPVHGV CTL line
(b) Donor 003 SLYNTVATL CTL clone 
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Production of β-chemokines and IFN-γ by HIV-1-specific CTLs: (a)
donor SC6 ILKEPVHGV CTL line (10 days post-restimulation) and (b)
donor 003 SLYNTVATL CTL clone (9 days post-restimulation). The
percentage lysis and production of β-chemokines and IFN-γ (in pg/ml)
are plotted against a range of effector:target ratios (E:T). Results are
shown for unpulsed targets, and for targets pulsed with the peptides
SLYNTVATL and ILKEPVHGV. Similar results were obtained with the
CTL lines and clones shown in Table 1 (data not shown). Autologous
or HLA-matched B-lymphoblastoid cell lines (B-LCL) were used as
targets in all assays. Targets were pulsed with 50 µM peptide, or
mock-pulsed with medium alone, for 90 min and washed twice prior to
assay. Lysis and cytokine release were determined at 4 h. Background
production of cytokines by target cells was minimal. IFN-γ release is
known to occur following TCR signalling and its measurement in these
initial assays was included as a methodological control. A degree of
cross-reactivity was observed with recombinant interleukin-2 in the
RANTES immunoassay. Although free peptide was not present in
these assays, a contribution to chemokine release from bystander lysis
(that is, lysis of neighbouring CTLs in the absence of cognate
recognition through the TCR) cannot be excluded [28]; CTLs lysed
with water (in the presence of broad spectrum protease inhibitors)
prior to antigen exposure, however, did not release significant amounts
of MIP-1α or MIP-1β, suggesting that simple cytoplasmic release from
CTLs acting as targets in assay cultures does not account for the
observed coupling of cytolytic activity with the release of these β-
chemokines. RANTES (as determined by immunoassay) was detected
in CTL lysates (data not shown). In time course experiments, MIP-1α,
MIP-1β and IFN-γ production was detected only after a lag phase of
approximately 90 min following antigen presentation, consistent with
regulation at the level of transcription; RANTES release, in contrast,
was observed within several minutes. These observations suggest that
RANTES is released from a pre-formed store within the CTLs.
Chemokine concentrations achieved by TCR triggering of CTLs
generally ranked MIP-1β > MIP-1α/RANTES. Background release of β-
chemokines (that is, release in the absence of peptide, or with an
unrelated peptide) by CTLs was most significant for RANTES, and
decreased with time from restimulation.
receptor blockade does not account fully for CD8+ lympho-
cyte-mediated inhibition of HIV-1 replication [2,5,16–20].
As yet poorly characterized secreted or cell-associated
factors with more potent suppressor activity may have a
greater effect on disease progression [16].
Chemokines play a central role in orchestrating host cel-
lular defences through their pro-inflammatory, chemoat-
tractant and cytomodulatory properties as well as
inhibiting entry of HIV-1 into cells [21–24]. Their release
by virus-specific CTLs following the recognition of an
infected host cell may be essential for the coordination of
an effective antiviral immune response [23]. Subversion
of these functions by antigenic variation could seriously
impair antiviral immunity, and so provide a potent mech-
anism of immune evasion. 
Materials and methods
Donors were either asymptomatic HIV-1-infected individuals from the
Oxford Haemophilia Centre or genitourinary clinics in the Oxford
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Current BiologyAFHHVAREL SLYNTVATL SLYNTVATL variants (3F, 3F/5A or 3S)
Effects of natural epitope variants on cytolysis and β-chemokine
production by the donor 868 HLA-A2-restricted SLYNTVATL-specific
CTL line (12 days post-restimulation). An E:T ratio of 6:1 was used in
each experiment. Lysis and β-chemokine release were measured at 6 h
and are plotted against peptide concentration. Results are shown for
the SLYNTVATL variants (a) 3F, (b) 3F/5A and (c) 3S and for the
peptides AFHHVAREL (HLA-A2-restricted peptide epitope
corresponding to amino acids 190–198 of Nef, included as a
specificity control) and SLYNTVATL in (a–c). Background production
of chemokines by the B-LCL targets in these assays was significant
only for MIP-1α (510 pg/ml) and was subtracted from experimental
values. These assays were performed in the presence of free peptide,
conditions under which CTL–CTL lysis may be significant [28]. Some
β-chemokine release may therefore be due to CTLs acting as targets in
culture, either throughout the assay (RANTES), or following activation
by antigen (MIP-1α and MIP-1β). Similar patterns were observed with
targets prepulsed with peptide (concentration 1 µM) and with free
peptide in the absence of targets (that is, with CTLs presenting
antigen to each other). Release of β-chemokines also paralleled
cytolysis with the 3C, 3L, 6I, 3F/6I, 6I/8V, 3F/8V and 3F/6I/8V peptide
variants (data not shown); these variants have been shown to bind
HLA-A2 [11]. Differences in the peptide sensitivity of these CTL
responses might reflect varying thresholds of detection, but previous
work has demonstrated that different CTL functions might be observed
at different levels of TCR occupancy [29].
region, or individuals with primary HIV-1 infection from the Chelsea and
Westminster Hospital, London. HLA type was determined by amplifica-
tion refractory mutation system (ARMS)–PCR with sequence-specific
primers [25]. Peptides were synthesized using standard fluorenyl-
methoxycarbonyl (Fmoc) techniques and were >90% pure as deter-
mined by high-pressure liquid chromatography (Research Genetics).
Peptide-specific CTL lines and clones were derived from donor periph-
eral blood mononuclear cells as described previously [26,27]; the
specificities and origins of the CTLs used in this work are described in
Table 1. CTLs were washed twice in RPMI-1640 (Sigma) and diluted
in fresh medium prior to assay. Cytolytic activity was determined using
standard 51Cr release methodology as described previously [27].
Supernatants were assayed for MIP-1α, MIP-1β, RANTES and IFN-γ
with commercially available quantitative immunoassays (R&D Systems);
standard calibration curves were constructed with each assay. All data
points shown represent the mean of duplicate assays.
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